Vetter ramps up global clinical manufacturing push with major US & Europe expansion
The goal is to better support drug developers as programs move from laboratory research into clinical trials
The goal is to better support drug developers as programs move from laboratory research into clinical trials
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Subscribe To Our Newsletter & Stay Updated